(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/125908 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2021/062824

(22) International Filing Date:
10 December 2021 (10.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/124,396 11 December 2020 (11.12.2020) US

(71) Applicant: **BOLT BIOTHERAPEUTICS, INC.** [US/US]; 900 Chesapeake Drive, Redwood City, California 94063 (US).

(72) Inventors: **ACKERMAN, Shelley Erin**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **ALONSO, Michael N.**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **DORNAN, David**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **KOWANETZ, Marcin**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **KUDIRKA, Romas**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **LEE, Arthur**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **MALLET, William**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **SAFINA, Brian**; 900 Chesapeake Drive, Redwood City, California 94063 (US). **ZHOU, Matthew**; 900 Chesapeake Drive, Redwood City, California 94063 (US).

(74) Agent: **ANDRUS, Alex** et al.; VIKSNINS HARRIS PADYS MALEN LLP, 7900 International Drive, Suite 410, Bloomington, MN 55425 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2022/125908 A1

(54) Title: ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF

(57) Abstract: The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.